Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP-2) trial: Study protocol for a randomized controlled trial

Trials

Volumn 13, Issue , 2012, Pages

  McAuley, Daniel F ^a,b   Laffey, John G ^c   O'Kane, Cecilia M ^a   Cross, Mark ^a,b   Perkins, Gavin D ^d   Murphy, Lynn ^b   McNally, Christine ^b   Crealey, Grainne ^b   Stevenson, Michael ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

^c NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^d UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Acute lung injury; Acute respiratory distress syndrome; Simvastatin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; SIMVASTATIN;

ACUTE LUNG INJURY; ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG URINE LEVEL; FOLLOW UP; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; IRELAND; LUNG DISEASE; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; ORGAN DYSFUNCTION SCORE; OUTCOME ASSESSMENT; OXYGENATION; PATIENT SAFETY; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; SURVIVAL RATE; UNITED KINGDOM;

ACUTE LUNG INJURY; CLINICAL PROTOCOLS; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; DRUG COSTS; GREAT BRITAIN; HOSPITAL COSTS; HOSPITAL MORTALITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IRELAND; LENGTH OF STAY; LUNG; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECOVERY OF FUNCTION; RESEARCH DESIGN; RESPIRATION, ARTIFICIAL; SIMVASTATIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84866158279     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-13-170     Document Type: Article

References (23)

1. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994, 149:818-824.
2. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, Hudson LD. Incidence and outcomes of acute lung injury. N Engl J Med 2005, 353:1685-1693. 10.1056/NEJMoa050333, 16236739.
3. Brun-Buisson C, Minelli C, Bertolini G, Brazzi L, Pimentel J, Lewandowski K, Bion J, Romand JA, Villar J, Thorsteinsson A, Damas P, Armaganidis A, Lemaire F, . ALIVE Study Group Epidemiology and outcome of acute lung injury in European intensive care units. Results from the ALIVE study. Intensive Care Med 2004, 30:51-61. 10.1007/s00134-003-2022-6, 14569423, ALIVE Study Group.
4. Irish Critical Care Trials Group Acute lung injury and the acute respiratory distress syndrome in Ireland: a prospective audit of epidemiology and management. Crit Care 2008, R30. Irish Critical Care Trials Group.
5. Erickson SE, Martin GS, Davis JL, Matthay MA, Eisner MD. Recent trends in acute lung injury mortality: 1996-2005. Crit Care Med 2009, 37:1574-1579. 10.1097/CCM.0b013e31819fefdf, 2696257, 19325464.
6. Herridge MS, Tansey CM, Matte A, Tomlinson G, Diaz-Granados N, Cooper A, Guest CB, Mazer CD, Mehta S, Stewart TE, Kudlow P, Cook D, Slutsky AS, Cheung AM, . Canadian Critical Care Trials Group Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med 2011, 364:1293-1304. 10.1056/NEJMoa1011802, 21470008, Canadian Critical Care Trials Group.
7. Rossi C, Simini B, Brazzi L, Rossi G, Radrizzani D, Iapichino G, Bertolini G. Variable costs of ICU patients: a multicenter prospective study. Intensive Care Med 2006, 32:545-552. 10.1007/s00134-006-0080-2, 16501946.
8. Cheung AM, Tansey CM, Tomlinson G, Diaz-Granados N, Matte A, Barr A, Mehta S, Mazer CD, Guest CB, Stewart TE, Al-Saidi F, Cooper AB, Cook D, Slutsky AS, Herridge MS. Two-year outcomes, health care use, and costs of survivors of acute respiratory distress syndrome. Am J Respir Crit Care Med 2006, 174:538-544. 10.1164/rccm.200505-693OC, 16763220.
9. Craig T, O'Kane CM, McAuley DF. Potential mechanisms by which statins modulate pathogenic mechanisms important in the development of acute lung injury. 27th Yearbook of Intensive Care and Emergency Medicine 2007, 276-288. Springer-Verlag, Berlin, Vincent JL.
10. Shyamsundar M, McKeown S, O'Kane C, Craig T, Brown V, Thickett DR, Matthay MA, Taggart C, Backmann J, Elborn JS, McAuley DF. Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med 2009, 179:1107-1114. 10.1164/rccm.200810-1584OC, 2695496, 19324974.
11. Craig TR, Duffy MJ, Shyamsundar M, McDowell C, O''Kane CM, Elborn JS, McAuley DF. A randomized clinical trial of hydroxymethylglutaryl- coenzyme a reductase inhibition for acute lung injury (The HARP Study). Am J Respir Crit Care Med 2011, 183:620-626. 10.1164/rccm.201003-0423OC, 20870757.
12. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials 2010, 11:32. 10.1186/1745-6215-11-32, 2857832, 20334632.
13. Gao Smith F, Perkins GD, Gates S, Young D, McAuley DF, Tunnicliffe W, Khan Z, Lamb SE. Effect of intravenous beta-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. Lancet 2012, 379:229-235. 10.1016/S0140-6736(11)61623-1, 3266479, 22166903.
14. Felton TW, Sander R, Al-Aloul M, Dark P, Bentley AM. Can a score derived from the Critical Care Minimum Data Set be used as a marker of organ dysfunction? - a pilot study. BMC Res Notes 2009, 2:77. 10.1186/1756-0500-2-77, 2688517, 19419551.
15. The EuroQol Group EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990, 16:199-208. The EuroQol Group.
16. The ARDS Network investigators Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Eng J Med 2000, 342:1301-1308. The ARDS Network investigators.
17. Matthay MA, Brower RG, Carson S, Douglas IS, Eisner M, Hite D, Holets S, Kallet RH, Liu KD, MacIntyre N, Moss M, Schoenfeld D, Steingrub J, Thompson BT. Randomized, placebo-controlled clinical trial of an aerosolized beta-agonist for treatment of acute lung injury. Am J Respir Crit Care Med 2011, 184:561-568. 3175548, 21562125.
18. Brower RG, Lanken PN, MacIntyre N, Matthay MA, Morris A, Ancukiewicz M, Schoenfeld D, Thompson BT. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med 2004, 351:327-336.
19. Mercat A, Richard JC, Vielle B, Jaber S, Osman D, Diehl JL, Lefrant JY, Prat G, Richecoeur J, Nieszkowska A, Gervais C, Baudot J, Bouadma L, Brochard L, . Expiratory Pressure (Express) Study Group Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA 2008, 299:646-655. 10.1001/jama.299.6.646, 18270353, Expiratory Pressure (Express) Study Group.
20. Kor DJ, Iscimen R, Yilmaz M, Brown MJ, Brown DR, Gajic O. Statin administration did not influence the progression of lung injury or associated organ failures in a cohort of patients with acute lung injury. Intensive Care Med 2009, 35:1039-1046. 10.1007/s00134-009-1421-8, 19183945.
21. Harvey S, Harrison DA, Singer M, Ashcroft J, Jones CM, Elbourne D, Brampton W, Williams D, Young D, Rowan K. Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial. Lancet 2005, 366:472-477. 10.1016/S0140-6736(05)67061-4, 16084255.
22. Excellence NIfHaC Guide to the Methods of Technology Appraisal 2008, NICE, London, Excellence NIfHaC.
23. Curtis LA. Unit Costs of Health and Social Care 2007 2007, Personal Social Services Research Unit, University of Kent, Canterbury.